Xilio Therapeutics, Inc. (XLO)
NASDAQ: XLO · Real-Time Price · USD
0.7180
-0.0280 (-3.75%)
Mar 31, 2025, 2:25 PM EDT - Market open
Xilio Therapeutics Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Xilio Therapeutics stock has a target of 4.00, which predicts an increase of 457.10% from the current stock price of 0.72.
Analyst Consensus: Buy
* Price targets were last updated on Nov 8, 2024.
Analyst Ratings
According to 1 stock analyst, the rating for Xilio Therapeutics is "Buy". This means that the analyst believes this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 0 | 0 | 0 | 0 | 0 |
| Buy | 2 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 1 | 1 | 1 | 1 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Raymond James | Raymond James | Buy Maintains $6 → $4 | Buy | Maintains | $6 → $4 | +457.10% | Nov 8, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +874.93% | May 30, 2023 |
| Chardan Capital | Chardan Capital | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +874.93% | May 11, 2023 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $20 → $10 | Buy | Maintains | $20 → $10 | +1,292.76% | Jan 27, 2023 |
| Chardan Capital | Chardan Capital | Strong Buy Initiates $7 | Strong Buy | Initiates | $7 | +874.93% | Dec 21, 2022 |
Financial Forecast
Revenue This Year
51.24M
from 6.34M
Increased by 707.71%
Revenue Next Year
64.81M
from 51.24M
Increased by 26.48%
EPS This Year
-0.32
from -1.09
EPS Next Year
-0.68
from -0.32
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 73.5M | 89.3M | 10.5M | ||
| Avg | 51.2M | 64.8M | 5.1M | ||
| Low | 22.7M | 31.9M | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 1,058.6% | 74.2% | -83.8% | ||
| Avg | 707.7% | 26.5% | -92.2% | ||
| Low | 258.4% | -37.8% | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -0.04 | -0.53 | -0.20 |
| Avg | -0.32 | -0.68 | -0.62 |
| Low | -0.69 | -0.78 | -1.23 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.